R

Rocket Pharmaceuticals
D

RCKT

11.750
USD
-0.16
(-1.34%)
مغلق
حجم التداول
56,551
الربح لكل سهم
-2
العائد الربحي
-
P/E
-4
حجم السوق
1,249,460,749
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ASTC
    -0.08000
    (-1.05%)
    7.56000 USD
    BA
    BA
    -0.510
    (-0.29%)
    172.550 USD
    GD
    GD
    -3.00
    (-1.13%)
    262.19 USD
    K
    KTOS
    -1.750
    (-6.42%)
    25.490 USD
    LMT
    LMT
    -7.55
    (-1.54%)
    483.00 USD
    M
    MAXR
    0
    (0%)
    0.000000 USD
    NOC
    NOC
    -12.92
    (-2.69%)
    467.42 USD
    RTX
    RTX
    -2.980
    (-2.54%)
    114.430 USD
    S
    SPCE
    -0.38000
    (-5.78%)
    6.19000 USD
    U
    U
    -2.340
    (-9.49%)
    22.330 USD
    المزيد
الأخبار

العنوان: Rocket Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.